Patients exhibiting lower KIR3DL2 expression levels displayed poorer prognosis, as evidenced by reduced overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS) rates, indicating a higher tendency for tumor recurrence and mortality (Figure 5D). Here, KIR3DL2 is linked to neoplasm.